NCBiotech News

We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.

Bioscience briefs with names making news

Durham-based Bioventus, a global orthobiologics company with growing sales revenues, has filed for a $150 million initial public offering (IPO) of stock.

 

-- Shutterstock image

Cempra is a Chapel Hill company that’s developing antibiotics to treat scary bacterial infections.

Cempra, a Chapel Hill company that’s developing antibiotics to treat scary bacterial infections, has filed for European Union (EU) authorization for market approval of its lead product, solithromycin.

Great news. And sadly for Cempra, it may also be the most convoluted form of lettergy to confront any mortal, any company, any news site or website in a hot while.

The NCBiotech Library will be undergoing a renovation from Friday, July 1 through Tuesday, July 12. If you need to use our market reports or databases, library services will be available by appointment.

To set up an appointment between July 1 and July 12, contact us at library@ncbiotech.org or 919-549-8880. Please schedule 24 hours in advance.

Veristat, a full-service clinical research organization (CRO) based in Southborough, Mass., says it will open an office in the Research Triangle area this fall.

Mayne Pharma Group, an Australian drug manufacturer with a growing production plant in Greenville, has agreed to acquire a portfolio of generic drugs from Teva Pharmaceutical Industries and Allergan for $652 million.

Growing demand for natural products by health-conscious consumers has prompted Gaia Herbs to begin a nearly $5 million expansion of its production facilities in Brevard.

If your early-stage life science company needs some funding help, you still have a few days to apply for a chance to pitch your company story to investors and colleagues at the 2016 annual Southeast BIO Investor & Partnering Forum.

As part of the celebration of the opening of SoBran's Greensboro animal research facility, the company and NCBiotech are co-sponsoring the Innovation for Impact Prize contest for researchers at North Carolina academic institutions and emerging companies – those with fewer than 50 employees and annual revenue under $10 million.

Traumatic brain injury has gained national prominence as star athletes have publicly acknowledged their struggles, and now the medical community is sounding the alarm about the prevalence of TBI among soldiers, who face comparable risks as they engage in rigorous training, athletics and combat.

BioFluidica, a Chapel Hill company developing a product using liquid biopsies for cancer detection. has completed a $2 million Series A funding round.

More than 125 participated in a day-long symposium at NCBiotech, exploring the bioterrorism challenges our defense and military agencies are charged with assessing and solving, and some of North Carolina's capabilities for helping to deal with the issues.

North Carolina’s life science jobs continue to grow at more than triple the national average, pushing the total number of people employed in the sector statewide above 70,000 for the first time.

CivaTech Oncology, a Research Triangle Park company developing cancer therapy devices with funding help from the North Carolina Biotechnology Center, is featured in an abstract that will get a “Best in Show” award at an upcoming scientific meeting.